Acute myelogenous leukemia stem cells: from Bench to Bedside. Review uri icon

Overview

abstract

  • Despite reaching remission with traditional chemotherapy, most adult patients with acute myeloid leukemia (AML) will relapse and die of their disease. Numerous studies have identified a rare subset of leukemia cells that evade traditional chemotherapy and are capable of self-renewal and initiating leukemia. These cells are thought to be responsible for relapse and are termed leukemia stem cells (LSCs). This article will review the current LSC translational research and focus on new approaches to detect LSC burden and its prognostic implications, as well as the identification and development of therapeutic agents active against LSCs.

publication date

  • June 17, 2012

Research

keywords

  • Leukemia, Myeloid
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells

Identity

PubMed Central ID

  • PMC4374350

Scopus Document Identifier

  • 84882924200

Digital Object Identifier (DOI)

  • 10.1016/j.canlet.2012.05.034

PubMed ID

  • 22713929

Additional Document Info

volume

  • 338

issue

  • 1